Breast cancer metastasis: Markers and models

Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nature reviews. Cancer (Impact Factor: 37.4). 09/2005; 5(8):591-602. DOI: 10.1038/nrc1670
Source: PubMed

ABSTRACT Breast cancer starts as a local disease, but it can metastasize to the lymph nodes and distant organs. At primary diagnosis, prognostic markers are used to assess whether the transition to systemic disease is likely to have occurred. The prevailing model of metastasis reflects this view--it suggests that metastatic capacity is a late, acquired event in tumorigenesis. Others have proposed the idea that breast cancer is intrinsically a systemic disease. New molecular technologies, such as DNA microarrays, support the idea that metastatic capacity might be an inherent feature of breast tumours. These data have important implications for prognosis prediction and our understanding of metastasis.

Download full-text


Available from: Laura J van 't Veer, Aug 11, 2015
41 Reads
  • Source
    • "A word of caution should be spent about the fact that the event considered in the INT case series was the occurrence of distant metastases, whereas only disease-specific death was available in the METABRIC data set. It is well known that the main cause of death for breast cancer is the development of metastasis at distant sites, rather than the primary tumor (Weigelt et al, 2005), which justifies our analyses in the second cohort. However, it should be noted that also patients untreated after surgery were likely to have received several treatments after relapse and before dying, and no information is available on this aspect. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer clinical outcome is affected by tumor molecular features, and the identification of subtype-specific prognostic biomarkers is relevant for breast cancer translational research. Gene expression signatures proved to be able to complement prognostic information provided by classical clinico-pathological features. Recently, microRNAs (miRNAs) have been causally linked to tumorigenesis and cancer progression and have been associated with patient outcome, also in breast cancer. MicroRNAs associated with the development of distant metastasis were identified in a cohort of 92 ESR1+/ERBB2- lymph node-negative breast cancers from patients not receiving adjuvant treatment. Results were confirmed and further investigated in a total of 1246 miRNA and gene expression profiles of the Molecular Taxonomy of Breast Cancer International Consortium data set. Moderated t-test, univariable and multivariable Cox regression models were used for statistical analyses. miR-30e* was identified as independent protective prognostic factor in lymph node-negative untreated patients with ESR1+/ERBB2- tumours and retained a significant association with a good prognosis in treated patients with the same tumor subtype as well as in the ERBB2+ subtype, but not in ESR1-/ERBB2- tumours. We highlighted a relevant and subtype-specific role in breast cancer for miR-30e* and demonstrated that adding miRNA markers to gene signatures and clinico-pathological features can help for a better prognostication.British Journal of Cancer advance online publication, 9 June 2015; doi:10.1038/bjc.2015.206
    British Journal of Cancer 06/2015; 113(2). DOI:10.1038/bjc.2015.206 · 4.84 Impact Factor
  • Source
    • "The main cause of death in these patients was its metastases at distant sites. Owing to difficulty in predicting metathesis development many women are over-treated and suffer toxic side effects of chemotherapy (Weigelt et al., 2005). Recent epidemiological studies suggested the presence of an inverse association between regular intake of NSAIDs and the relative risk of breast cancer (Harris et al., 2005; Harris et al., 1995; Harris et al., 1996). "
    Bangladesh Journal of Pharmacology 03/2015; 10(1). DOI:10.3329/bjp.v10i1.21599 · 1.05 Impact Factor
  • Source
    • "There were many independent risk factors of breast cancer recurrence, containing tumor size, node involvement, grade, lymphatic vascular invasion, the status of ER and HER2 and so on(Kennecke et al., 2010). As inability to accurately predict the risk of metastasis in individuals, 80% of the patients received adjuvant chemotherapy even though only about 40% of the patients would undergo relapse and then die of cancer metastases(Weigelt et al., 2005). Thus, many patients that could be cured by local treatment such as surgery therapy and radiation therapy conducted over treatment resulting in suffering unnecessary side effects induced by chemotherapy. "
    01/2015; DOI:10.5376/cge.2015.03.0002
Show more